Compare CSV & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSV | GYRE |
|---|---|---|
| Founded | 1991 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.5M | 759.1M |
| IPO Year | 1996 | 2004 |
| Metric | CSV | GYRE |
|---|---|---|
| Price | $48.58 | $8.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $59.00 | $17.00 |
| AVG Volume (30 Days) | ★ 89.8K | 71.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 54.76 | N/A |
| EPS | ★ 3.25 | 0.02 |
| Revenue | ★ $417,440,000.00 | $275,000.00 |
| Revenue This Year | $7.35 | $19.88 |
| Revenue Next Year | $3.87 | N/A |
| P/E Ratio | ★ $14.96 | $406.00 |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $38.10 | $6.58 |
| 52 Week High | $49.41 | $11.77 |
| Indicator | CSV | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 58.20 |
| Support Level | $43.62 | $7.23 |
| Resistance Level | $49.29 | $8.41 |
| Average True Range (ATR) | 1.07 | 0.23 |
| MACD | 0.18 | 0.13 |
| Stochastic Oscillator | 87.94 | 79.23 |
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.